Shares of Moderna, Inc. jumped 4% in morning trading as the COVID-19 vaccine manufacturer reported strong 4Q revenues of $571 million versus $14 million in 4Q FY19. Analysts were expecting revenues of $279.4 million. However, Moderna’s (MRNA) net loss per share widened to $0.69 versus $0.37 in 4Q FY19. Analysts were expecting a loss per share of $0.35. Moderna’s CEO Stéphane Bancel said, “It is encouraging and humbling that more than 32 million doses of our [Covid-19] vaccine have been administered in the U.S. and that millions of people around the world have been vaccinated with our vaccine to date.